News 2020-05-13
Porton Shanghai Formulation R&D Center Launched Construction
Shanghai, China, May 13, 2020 - Porton Pharmatech Co. ,Ltd. (Porton Pharmatech), a subsidiary of Porton Pharma Solutions Ltd. (Porton, Stock Code: 300363), today announced the commencement of construction of its Shanghai R&D Center, which would be Porton’s third formulation lab site that has been constructed since 2019. It has previously started design and construction of two other formulation labs based in Chongqing, China and New Jersey，USA.
Others
More
News 2025-04-16
Porton Advanced's End-to-End CDMO Solutions Accelerates IND Approval of Tasly's Innovative Dual-Targeting CAR-T Therapy
April 12, 2025 - Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD’s Innovative Dual-Targeting CAR-T Therapy, "P134 Cell Injection," which has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) (Approval No.: 2025LP01030). This breakthrough CAR-T therapy is indicated for recurrent glioblastoma (GBM).
News 2025-04-11
Porton Newsletter - Q1 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities
